Image of Natasha Archer

Natasha Archer, MD

Instructor in Pediatrics and a Department of Global Health and Social Medicine Affiliate

Natasha Archer, MD, MPH, is a pediatric hematologist/oncologist at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, an instructor in pediatrics at Harvard Medical School, and associate physician in the Division of Global Health Equity at Brigham and Women’s Hospital. She is also the senior health and policy advisor for Hematology at Zanmi Lasante (the Haitian sister organization of Partners In Health). Dr. Archer’s research focuses on the delivery of effective sickle cell disease care to children worldwide. Her research interests include the implementation of sickle cell disease screening and management programs in low resource settings and the effect of different hemoglobins on malaria infectivity. Dr. Archer completed her fellowship in pediatric hematology/oncology at Dana-Farber/Boston Children’s in 2014 and her medicine and pediatrics residency in the Harvard Combined Internal Medicine/Pediatrics Residency training program in 2011. She also completed the Doris and Howard Hiatt Global Health Equity Residency in 2011. Dr. Archer earned her BS from Yale College in 1999, her MD from Yale University School of Medicine in 2006, and her MPH from Harvard School of Public Health in 2011.

Erythrocyte ion content and dehydration modulate maximal Gardos channel activity in KCNN4 V282M/+ Hereditary Xerocytosis (HX) red cells.
Authors: Authors: Rivera A, Vandorpe DH, Shmukler BE, Andolfo I, Iolascon A, Archer NM, Shabani E, Auerbach M, Hamerschlak N, Morton J, Wohlgemuth JG, Brugnara C, Snyder LM, Alper SL.
Am J Physiol Cell Physiol
View full abstract on Pubmed
Capacity building and networking to make newborn screening for sickle cell disease a reality in Haiti.
Authors: Authors: Saint Fleur R, Archer N, Hustace T, Louis RJ, Bellevue R, Gautier J, Lerebours E, Voltaire M, Alvarez O.
Blood Adv
View full abstract on Pubmed
Resistance to Plasmodium falciparum in sickle cell trait erythrocytes is driven by oxygen-dependent growth inhibition.
Authors: Authors: Archer NM, Petersen N, Clark MA, Buckee CO, Childs LM, Duraisingh MT.
Proc Natl Acad Sci U S A
View full abstract on Pubmed
Knowledge of Blood Group Decreases von Willebrand Factor Panel Testing in Children.
Authors: Authors: Archer NM, Forbes PW, Brugnara C.
Hemasphere
View full abstract on Pubmed
Pediatric sialoblastoma: Evaluation and management.
Authors: Authors: Irace AL, Adil EA, Archer NM, Silvera VM, Perez-Atayde A, Rahbar R.
Int J Pediatr Otorhinolaryngol
View full abstract on Pubmed
An Increased Risk of Second Malignant Neoplasms After Rhabdomyosarcoma: Population-Based Evidence for a Cancer Predisposition Syndrome?
Authors: Authors: Archer NM, Amorim RP, Naves R, Hettmer S, Diller LR, Ribeiro KB, Rodriguez-Galindo C.
Pediatr Blood Cancer
View full abstract on Pubmed
2015 Clinical trials update in sickle cell anemia.
Authors: Authors: Archer N, Galacteros F, Brugnara C.
Am J Hematol
View full abstract on Pubmed
The utility of the DDAVP challenge test in children with low von Willebrand factor.
Authors: Authors: Archer NM, Samnaliev M, Grace R, Brugnara C.
Br J Haematol
View full abstract on Pubmed
Diagnosis of iron-deficient states.
Authors: Authors: Archer NM, Brugnara C.
Crit Rev Clin Lab Sci
View full abstract on Pubmed
Diagnosis of iron-deficient states.
Authors: Authors: Archer NM, Brugnara C.
Crit Rev Clin Lab Sci
View full abstract on Pubmed